uric acid has been researched along with Tachycardia, Ventricular in 2 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The uric acid (UA) level is related to cardiac events and mortality, but little is known about the clinical significance of serum UA with regard to the ventricular tachyarrhythmia (VT) risk in patients with heart failure." | 7.88 | Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator. ( Kamioka, M; Kaneshiro, T; Matsumoto, Y; Nodera, M; Ohira, T; Suzuki, H; Takeishi, Y; Yoshihisa, A, 2018) |
| "The uric acid (UA) level is related to cardiac events and mortality, but little is known about the clinical significance of serum UA with regard to the ventricular tachyarrhythmia (VT) risk in patients with heart failure." | 3.88 | Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator. ( Kamioka, M; Kaneshiro, T; Matsumoto, Y; Nodera, M; Ohira, T; Suzuki, H; Takeishi, Y; Yoshihisa, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nodera, M | 1 |
| Suzuki, H | 1 |
| Matsumoto, Y | 1 |
| Kamioka, M | 1 |
| Kaneshiro, T | 1 |
| Yoshihisa, A | 1 |
| Ohira, T | 1 |
| Takeishi, Y | 1 |
| Tecder-Unal, M | 1 |
| Kanzýk, Y | 1 |
2 other studies available for uric acid and Tachycardia, Ventricular
| Article | Year |
|---|---|
Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator.
Topics: Aged; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography; Female; Heart Failur | 2018 |
Peroxynitrite in reperfusion arrhythmias and its whole blood chemiluminescence results.
Topics: Animals; Blood Pressure; Catalase; Drug Administration Schedule; Drug Therapy, Combination; Enzyme I | 2004 |